Q-omics provides the consensus-scored FBXW10 profile across patient tissues and cancer cell-line models. FBXW10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXW10 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, FBXW10 RNA expression shows 17,720 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where FBXW10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXW10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXW10 survival associations across molecular data types. FBXW10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXW10 RNA expression–survival associations across cancer types. High FBXW10 expression shows unfavorable associations in KIRC, ACC, KICH and COAD, but favorable associations in UCS and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXW10 RNA expression.
This table summarizes FBXW10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FBXW10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXW10 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LIHC, PAAD and STAD. The THCA box plot shows higher FBXW10 RNA expression in normal versus tumor tissue (log2 FC = −0.658, t-test p < 0.001).
This table shows molecular features associated with FBXW10 in patient tissues and cancer cell lines. In patient samples, FBXW10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXW10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
